Literature DB >> 30883511

Concentration-Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges.

Christoph Hiemke1.   

Abstract

BACKGROUND: Despite the obvious potential of Therapeutic Drug Monitoring (TDM) as a tool to optimize psychopharmacotherapy, especially treatment with mood-stabilizing, antidepressant and antipsychotic drugs, acceptance of TDM as a routine tool is still limited. A serious scientific argument against the regular use of TDM is the lack of evidence for a concentration-dependent clinical effect. The aim of this review was to highlight methodological problems leading to poor or even negative concentration-effect relationships and to show how therapeutically effective concentrations of psychoactive drugs can be determined using routine TDM databases.
METHODS: Reports on concentration-effect relationships of psychoactive drugs were analyzed with regard to applied methods. From routine TDM databases of patients who had been treated with antidepressant or antipsychotic drugs and whose improvement was measured by the clinical global impressions scale, mean and median drug concentrations were calculated and compared with reference ranges recommended by TDM guidelines.
RESULTS: Few fixed-dose studies with adequate design and data analysis demonstrated a correlation between drug concentration and clinical effect for psychoactive drugs. Most studies, however, mostly retrospective analyses of TDM databases, failed to find significant concentration-effect relationships because of flexible dosing. They were not suitable for the determination of therapeutically effective drug concentrations. Using TDM databases of antidepressant and antipsychotic drug concentrations in blood of patients who were categorized as responders by the clinical global impressions score, the interquartile ranges of drug concentrations (25th-75th percent range) can be shown to be very close to the therapeutic reference ranges recommended in guidelines for TDM in psychiatry.
CONCLUSIONS: This review provides a discussion on why simple correlation analyses of psychoactive drug concentrations in blood and clinical effects are obsolete for flexible-dose studies or TDM databases. TDM databases, however, can and should be used to calculate drug concentrations in blood of patients who had responded to the drugs. Interquartile ranges can be regarded and used as preliminary therapeutic reference ranges.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30883511     DOI: 10.1097/FTD.0000000000000582

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  11 in total

1.  Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring.

Authors:  Maria Shipkova; Uwe Christians
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

2.  The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.

Authors:  J A Arnaiz; C Rodrigues-Silva; G Mezquida; S Amoretti; M J Cuesta; D Fraguas; A Lobo; A González-Pinto; M C Díaz-Caneja; I Corripio; E Vieta; I Baeza; A Mané; C García-Rizo; M Bioque; J Saiz; M Bernardo; S Mas
Journal:  Psychopharmacology (Berl)       Date:  2020-11-23       Impact factor: 4.530

Review 3.  Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.

Authors:  Xenia M Hart; Christoph Hiemke; Luzie Eichentopf; Xenija M Lense; Hans Willi Clement; Andreas Conca; Frank Faltraco; Vincenzo Florio; Jessica Grüner; Ursula Havemann-Reinecke; Espen Molden; Michael Paulzen; Georgios Schoretsanitis; Thomas G Riemer; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2022-10-05       Impact factor: 4.415

Review 4.  A systematic review and combined meta-analysis of concentration of oral amisulpride.

Authors:  Lin Li; Lu Li; De-Wei Shang; Yu-Guan Wen; Yu-Ping Ning
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

5.  A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.

Authors:  J Kevin Hicks; Jeffrey R Bishop; Roseann S Gammal; Katrin Sangkuhl; Chad A Bousman; J Steven Leeder; Adrián Llerena; Daniel J Mueller; Laura B Ramsey; Stuart A Scott; Todd C Skaar; Kelly E Caudle; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-10-30       Impact factor: 6.875

6.  Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.

Authors:  R Taurines; S Fekete; A Preuss-Wiedenhoff; A Warnke; C Wewetzer; P Plener; R Burger; M Gerlach; M Romanos; K M Egberts
Journal:  J Neural Transm (Vienna)       Date:  2022-03-18       Impact factor: 3.850

7.  Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews.

Authors:  Xenia M Hart; Luzie Eichentopf; Xenija Lense; Thomas Riemer; Katja Wesner; Christoph Hiemke; Gerhard Gründer
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

8.  Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors.

Authors:  Cleo S M Funk; Xenia M Hart; Gerhard Gründer; Christoph Hiemke; Björn Elsner; Reinhold Kreutz; Thomas G Riemer
Journal:  Front Psychiatry       Date:  2022-02-21       Impact factor: 4.157

9.  Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions.

Authors:  Georgios Schoretsanitis; Ekkehard Haen; Daria Piacentino; Andreas Conca; Katharina Endres; Fabio Carpi; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2021-06-18       Impact factor: 6.447

10.  Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents.

Authors:  Sanne M Kloosterboer; Karin M Egberts; Brenda C M de Winter; Teun van Gelder; Manfred Gerlach; Manon H J Hillegers; Gwen C Dieleman; Soma Bahmany; Catrien G Reichart; Emma van Daalen; Mirjam E J Kouijzer; Bram Dierckx; Birgit C P Koch
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.